Advertisement
U.S. markets open in 3 hours 30 minutes
  • S&P Futures

    5,203.00
    -11.75 (-0.23%)
     
  • Dow Futures

    39,169.00
    -54.00 (-0.14%)
     
  • Nasdaq Futures

    18,178.00
    -53.50 (-0.29%)
     
  • Russell 2000 Futures

    2,042.50
    -7.30 (-0.36%)
     
  • Crude Oil

    82.60
    -0.12 (-0.15%)
     
  • Gold

    2,156.20
    -8.10 (-0.37%)
     
  • Silver

    25.09
    -0.17 (-0.69%)
     
  • EUR/USD

    1.0841
    -0.0035 (-0.33%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.60
    +0.27 (+1.88%)
     
  • GBP/USD

    1.2674
    -0.0054 (-0.43%)
     
  • USD/JPY

    150.6750
    +1.5770 (+1.06%)
     
  • Bitcoin USD

    64,158.52
    -3,654.55 (-5.39%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,720.07
    -2.48 (-0.03%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China

Feb 7 (Reuters) - Arqule Inc:

* ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA

* ARQULE INC - ‍DEAL TERMS INCLUDE AN UPFRONT PAYMENT TO ARQULE OF $3 MILLION AND AN ADDITIONAL $2.5 MILLION DEVELOPMENT MILESTONE WITHIN FIRST YEAR​

* ARQULE INC - ARQULE IS ALSO ELIGIBLE FOR REGULATORY AND COMMERCIAL MILESTONES AND ROYALTIES ON FUTURE SALES OF DERAZANTINIB IN GREATER CHINA

* ARQULE INC - COLLABORATION BETWEEN CO AND ROIVANT WILL EXPAND CLINICAL DEVELOPMENT OF DERAZANTINIB

* ARQULE - ‍ GRANTED A ROIVANT UNIT AN EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE DERAZANTINIB IN PEOPLE'S REPUBLIC OF CHINA, HONG KONG, MACAU, TAIWAN​ Source text for Eikon: Further company coverage:

Advertisement